TT-00420

Simultaneous inhibition of multiple pathways is strongly recommended to treat certain heterogeneous diseases such as TNBC, considering very limited clinical benefit from single target therapy in the clinical trials. TT-00420 is a spectrum selective multi-target kinase inhibitor. It selectively blocks three signal pathways including cell cycles, JAK/STAT, and receptor tyrosine kinases. In-house MOA studies demonstrate the requirement of the above three-pathway inhibition to show synergistic activity towards majority of TNBC cell lines. TT-00420 also demonstrates the ability to modulate tumor-microenvironment, possessing a dual mechanistic property of both targeted therapy and immuno-oncology aspect. TT-00420 has demonstrated excellent efficacy and good safety profile. It is under clinical studies in both the US and China.




TT-00920

PDE9, so-called the “missing culprit” in heart failure, regulates natriuretic peptide-stimulated cGMP pathway in the heart. PDE9 is highly elevated in human failing hearts, which impedes a natural protective pathway and makes the heart more vulnerable to fail. Genetic inhibition of PDE9 reversed existing heart failure in preclinical animal model. TT-00920 is a potent, selective and low brain-penetrant small molecule inhibitor of PDE9. It is expected to enter clinical trials in late 2019.